<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04098744</url>
  </required_header>
  <id_info>
    <org_study_id>J1991</org_study_id>
    <secondary_id>IRB00219993</secondary_id>
    <secondary_id>2020 0237</secondary_id>
    <nct_id>NCT04098744</nct_id>
  </id_info>
  <brief_title>Artesunate Vaginal Inserts for the Treatment of CIN2/3</brief_title>
  <acronym>ART_CIN_II</acronym>
  <official_title>A Phase II Double Blind, Placebo-controlled, Randomized Trial of Artesunate Vaginal Inserts for the Treatment of Patients With Cervical Intraepithelial Neoplasia (CIN2/3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Frantz Viral Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amarex Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Frantz Viral Therapeutics, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal
      inserts for the treatment of women who have cervical high grade intraepithelial neoplasia
      (CIN2/3).

      Participants who receive placebo in this study have the option to receive active drug
      (artesunate) after their week 15 colposcopy visit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible participants in this study are randomized to receive either artesunate or placebo
      vaginal inserts for the treatment of CIN2/3. Both groups receive three 5-day cycles of the
      respective drug, at weeks 0, 2, and 4. Participants are followed closely with colposcopies at
      weeks 6, 15, and 28. After the week 15 colposcopy visit the investigator is unblinded.
      Participants in the placebo group who still have CIN2/3 have the option to start treatment
      with artesunate within 4 weeks. Participants in the artesunate treatment who still have
      CIN2/3 at the week 15 visit, will undergo standard of care surgical treatment (LEEP or cold
      knife conization) within 6 weeks.

      Primary Objective: To evaluate the histopathologic response to three 5-day cycles of
      artesunate vaginal inserts in adult females with biopsy-proven HPV-associated CIN 2/3.

      Secondary Objectives:

        -  To evaluate the safety of artesunate vaginal inserts for the treatment of CIN2/3

        -  To evaluate the viral clearance after three 5-day cycles of artesunate vaginal inserts
           in adult females with biopsy-proven HPV-associated CIN 2/3.

        -  To evaluate histopathologic regression after the week 15 time point
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with histologic regression to cervical intraepithelial neoplasia (CIN) 1 or less by week 15</measure>
    <time_frame>15 weeks</time_frame>
    <description>Number of participants who have histologic regression of CIN2/3 to CIN1 within the study window (15 weeks)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants who have achieved clearance of detectable human papilloma virus (HPV) by week 15</measure>
    <time_frame>15 weeks</time_frame>
    <description>Number of participants who had HPV strains detected at study entry which become undetectable within the study window (15 weeks)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with Treatment-Emergent Adverse Events (TEAE)</measure>
    <time_frame>28 weeks</time_frame>
    <description>Number of participants who had adverse events, as defined by CTCAE v5.0, related to the study intervention</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants who withdrew from the study due to TEAEs</measure>
    <time_frame>28 weeks</time_frame>
    <description>Number of participants who were withdrawn from the study due to adverse events related to the study drug</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>CIN 2/3</condition>
  <condition>HPV Infection</condition>
  <condition>Pre-Cancerous Dysplasia</condition>
  <condition>Cervical Dysplasia</condition>
  <arm_group>
    <arm_group_label>Artesunate vaginal insert</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive three 5-day cycles of artesunate vaginal inserts, 200mg/day, at week 0, week 2, week 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo vaginal inserts</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive three 5-day cycles of placebo vaginal inserts, at week 0, week 2, and week 4. Unblinding will take place at week 15. Participants who do not have histologic regression at week 15 will have the opportunity to cross over to the experimental arm, and start treatment with artesunate vaginal inserts within 4 weeks of the week 15 visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artesunate vaginal insert</intervention_name>
    <description>Artesunate formulated as vaginal inserts, 200mg</description>
    <arm_group_label>Artesunate vaginal insert</arm_group_label>
    <other_name>Artesunic acid</other_name>
    <other_name>DHA</other_name>
    <other_name>artemisinin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo vaginal insert</intervention_name>
    <description>Placebo for artesunate vaginal inserts</description>
    <arm_group_label>Placebo vaginal inserts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult females age ≥ 18 years

          -  Capable of informed consent

          -  Any HPV genotype detectable by DNA test/HPV genotyping

          -  Colposcopically-directed, histologically confirmed tissue diagnosis of either CIN2,
             CIN3, or CIN2/3

          -  Women of childbearing potential agree to use birth control through week 28 of the
             study.

          -  Weight ≥ 50kg

        Exclusion Criteria:

          -  Pregnant and nursing women

          -  Active autoimmune disease

          -  Taking immunosuppressive medication

          -  HIV seropositivity

          -  Immunocompromised subjects

          -  Evidence of concurrent cervical adenocarcinoma in situ

          -  Concurrent malignancy except for nonmelanoma skin lesions, because treatment for other
             cancers have systemic effects
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>This study is for women only as it is a treatment for cervical intraepithelial neoplasia (CIN2/3)</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cornelia L Trimble, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mihaela Plesa, BA</last_name>
    <phone>443-695-5243</phone>
    <email>mplesa@frantzgroup.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmad Bayat, MD</last_name>
    <phone>(301) 956-2523</phone>
    <email>ahmadb@amarexcro.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins Outpatient Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Cornelia Trimble, MD</last_name>
      <phone>410-502-0512</phone>
      <email>ctrimbl@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Maria Hom</last_name>
      <phone>410-502-0512</phone>
      <email>mhom3@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Cornelia L Trimble, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Harris Health System</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77026</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jessica Gallegos</last_name>
      <phone>713-563-4580</phone>
      <email>jrgalleg@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Cindy Melendez</last_name>
      <phone>713-563-4582</phone>
      <email>cvmelend@mdanderson.org</email>
    </contact_backup>
    <investigator>
      <last_name>Andrea Milbourne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathleen Schmeler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 19, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>treatment study</keyword>
  <keyword>cancer prevention</keyword>
  <keyword>non-surgical</keyword>
  <keyword>HPV disease</keyword>
  <keyword>CIN</keyword>
  <keyword>topical treatment</keyword>
  <keyword>vaginal inserts</keyword>
  <keyword>artesunate</keyword>
  <keyword>artemisinin</keyword>
  <keyword>non-invasive</keyword>
  <keyword>high risk HPV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Uterine Cervical Dysplasia</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

